Abstract 1009P - Integrated biomarker analysis of brigatinib efficacy in Anaplastic Lymphoma Kinase-positive (ALK+) non-small cell lung cancer (NSCLC) refractory to alectinib

  Abstract 1156P - Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK+) non‒small cell lung cancer (NSCLC): results from the ALTA-1L trial

  Abstract 988P - Phase 1/2 study of mobocertinib in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Updated results from platinum- pretreated patients (PPP)

  Abstract 1087P - Predictive value of Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D) in patients (pts) with EGFR exon 20 insertion (ex20ins)‒positive metastatic non‒small cell lung cancer (mNSCLC) receiving mobocertinib therapy

  Abstract 1111P - Real-world treatment duration in patients with non-small cell lung cancer (NSCLC) with EGFR Exon20 insertion (EGFRex20ins) mutations receiving mobocertinib through the global expanded access program (EAP)

  Abstract 1001P - Epidermal growth factor receptor (EGFR) testing and treatment patterns associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US

For Healthcare Professionals Only
VV-MEDMAT-74116 Sep 2022